BCYCBicycle Therapeutics plc

BCYC Stock Price, Valuation & Chart | Bicycle Therapeutics plc

Compare

$4.300+0.20 (+4.88%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology BCYC intrinsic value BCYC calculated fair value vs price

Overview Financials Dividends Ratios

BCYC Historical price chart

BCYC Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization298.40M

PE Ratio-1.58

EPS-2.73

Trading Volume317.57K

Today's High/Low4.39/4.1

Dividend Yield0.00

52 Week High/Low9.16/3.75

Shares Outstanding69.39M

BCYC Financial Statement

BCYC Analyst ratings

BCYC Analysis & performance metrics

BCYC Company profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead…

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also…

BCYC Management team

Name

Position

Alistair MilnesCOO

Chief Operating Officer

Alethia Rene YoungCFO

Chief Financial Officer

Christian Heinis

Scientific Founder

Stephanie Yao

Senior Vice President of Investor Relations and Corporate Communications

Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE, Ph.D.CTO

Co-Founder & Non-Executive Director

Travis Thompson

Senior Vice President, Chief Accounting Officer & Principal Accounting Officer

Michael Skynner B.sc. Ph.d., Ph.D.CTO

Chief Technology Officer

Kevin Lee M.B.A., Ph.D.CEO

Chief Executive Officer & Executive Director

Name

Position

Alistair MilnesCOO

Chief Operating Officer

Alethia Rene YoungCFO

Chief Financial Officer

Christian Heinis

Scientific Founder

Stephanie Yao

Senior Vice President of Investor Relations and Corporate Communications

Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE, Ph.D.CTO

Co-Founder & Non-Executive Director

Travis Thompson

Senior Vice President, Chief Accounting Officer & Principal Accounting Officer

Michael Skynner B.sc. Ph.d., Ph.D.CTO

Chief Technology Officer

Kevin Lee M.B.A., Ph.D.CEO

Chief Executive Officer & Executive Director

Management Team

Alistair MilnesCOO

Chief Operating Officer

Alethia Rene YoungCFO

Chief Financial Officer

Christian Heinis

Scientific Founder

Stephanie Yao

Senior Vice President of Investor Relations and Corporate Communications

Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE, Ph.D.CTO

Co-Founder & Non-Executive Director

Travis Thompson

Senior Vice President, Chief Accounting Officer & Principal Accounting Officer

Michael Skynner B.sc. Ph.d., Ph.D.CTO

Chief Technology Officer

Kevin Lee M.B.A., Ph.D.CEO

Chief Executive Officer & Executive Director

Management

Alistair MilnesCOO

Chief Operating Officer

Alethia Rene YoungCFO

Chief Financial Officer

Christian Heinis

Scientific Founder

Stephanie Yao

Senior Vice President of Investor Relations and Corporate Communications

Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE, Ph.D.CTO

Co-Founder & Non-Executive Director

Travis Thompson

Senior Vice President, Chief Accounting Officer & Principal Accounting Officer

Michael Skynner B.sc. Ph.d., Ph.D.CTO

Chief Technology Officer

Kevin Lee M.B.A., Ph.D.CEO

Chief Executive Officer & Executive Director

Total 8 executives

BCYC Frequently asked questions

What is Bicycle Therapeutics plc (BCYC) Stock Price?

Current stock price of Bicycle Therapeutics plc (BCYC) stock is $4.300. The stock price is +4.88% higher in the session. The intraday range can be seen from this page. Volume of Bicycle Therapeutics plc (BCYC) stock is 317.57K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Bicycle Therapeutics plc (BCYC) stock price going up or down today?

The stock price of Bicycle Therapeutics plc (BCYC) can change with earnings, company news, and overall market sentiment. Bicycle Therapeutics plc operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Bicycle Therapeutics plc stock expensive at its current price?

Whether Bicycle Therapeutics plc looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for BCYC on this page is -1.58. EPS on this page is -2.73. Compare those figures with peers and growth expectations before deciding if the current Bicycle Therapeutics plc price is justified.

How has the stock price of Bicycle Therapeutics plc (BCYC) performed historically?

Historical performance for Bicycle Therapeutics plc (BCYC) is shown on the price chart on this page. Review multi-period moves alongside volume to see how BCYC reacted to past earnings and market events.

Should I buy Bicycle Therapeutics plc (BCYC) stock, at this price?

Buying Bicycle Therapeutics plc (BCYC) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.